EU Clinical Trial 2018-003748-22

PRISM: An Open-label, Multi-Center Extension Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) Following Systemic Treatment in Subjects with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype, Who Have Completed the SOLAR Study  May 21, 2019

Main objective of the trial: The primary objective of the study is to evaluate the efficacy of cobomarsen in subjects with MF who have shown disease progression following treatment with vorinostat in the SOLAR study. El objetivo principal del estudio es evaluar la eficacia de cobomarsen en sujetos con MF en lo que sehaya confirmado la progresión de la enfermedad después del tratamiento con vorinostat en el estudio SOLAR.

Parties

Sponsors
Countries
AT AU BE CA DE ES FR GB IT NL US
Keywords
COBOMARSEN MRG-106 Mycosis fungoides cobomarsen

JSON preview

Similar records

Title

Source:  EMA Last updated:  May 30, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.